Eptacog-alfa [activated recombinant factor VII] is an effective, well-tolerated therapy in haemophilia patients with inhibitors

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1572, 2007-01, pp. : 16-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recombinant Factor VIIa (Eptacog Alfa): A Pharmacoeconomic Review of its Use in Haemophilia in Patients with Inhibitors to Clotting Factors VIII or IX

By Lyseng-Williamson Katherine A.   Plosker Greg L.  

PharmacoEconomics, Vol. 25, Iss. 12, 2007-01 ,pp. : 1007-1029

Adis International

Access to resources Recommend Favorite

Recombinant Factor VIIa (Eptacog Alfa): A Review of its Use in Congenital or Acquired Haemophilia and Other Congenital Bleeding Disorders

By Siddiqui M. Asif A.   Scott Lesley J.  

Drugs, Vol. 65, Iss. 8, 2005-01 ,pp. : 1161-1177

Adis International

Access to resources Recommend Favorite

Inhaled treprostinil is an effective, well-tolerated add-on therapy for patients with pulmonary arterial hypertension (PAH) treated with bosentan

By  

Inpharma, Vol. 1, Iss. 1561, 2006-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Determinants of Drug Costs in Hospitalised Patients with Haemophilia: Impact of Recombinant Activated Factor VII

By Galanaud J.P.  

PharmacoEconomics, Vol. 21, Iss. 10, 2003-01 ,pp. : 699-707

Adis International

Access to resources Recommend Favorite

Eptacog alfa [recombinant factor VIIa] reduces perioperative blood loss in patients undergoing retropubic prostatectomy

By  

Inpharma, Vol. 1, Iss. 1371, 2003-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite